The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.
 
Suthee Rapisuwon
Research Funding - Bristol-Myers Squibb
 
Sapna Pradyuman Patel
Consulting or Advisory Role - Cardinal Health; Castle Biosciences; Incyte
Speakers' Bureau - Merck
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Provectus (Inst); Reata Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Cardinal Health; Castle Biosciences; Incyte; Massachusetts General Hospital; PCME, Rockpointe; Socrates Analytics
 
Richard D. Carvajal
Consulting or Advisory Role - Aura Biosciences; Bristol-Myers Squibb; Castle Biosciences; Chimeron Bio; Compugen; Foundation Medicine; Genentech/Roche; Genzyme; I-Mab; Iconic Therapeutics; Immunocore; Incyte; Janssen Oncology; Merck; PureTech; Rgenix; Sorrento Therapeutics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Roche/Genentech (Inst)
 
Leonel Fernando Hernandez-Aya
Consulting or Advisory Role - Massive Bio
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Immunocore (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Polynoma (Inst); Regeneron (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Sanofi/Regeneron
 
Katy K. Tsai
Consulting or Advisory Role - Compugen; Pulse Biosciences
Research Funding - Bayer (Inst); Ignyta (Inst); Novartis (Inst); takeda (Inst)
 
Sunandana Chandra
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Regeneron
Speakers' Bureau - Array BioPharma; Bristol-Myers Squibb; Regeneron
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Regeneron
 
Ming Tony Tan
Honoraria - AstraZeneca; Incyte; Otsuka; Sanofi Pasteur
Consulting or Advisory Role - American Gene Technologies
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Otsuka
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - Genoptix; GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Jeffrey Alan Sosman
Honoraria - Bristol-Myers Squibb; Genentech; MSD Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; MSD Oncology
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)